TY - JOUR
T1 - Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years
AU - Lachowiez, Curtis
AU - Cook, Rachel J.
AU - Hayes-Lattin, Brandon
AU - Maziarz, Richard T.
AU - Borate, Uma
AU - Traer, Elie
AU - Leonard, Jessica
AU - Newell, Laura
AU - Dao, Kim Hien
AU - Meyers, Gabrielle
N1 - Publisher Copyright:
© 2019
PY - 2019/6
Y1 - 2019/6
N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade, as understanding of the treatment and its related toxicities has led to changes in patient selection, conditioning regimens, and post-transplant care. Older (age ≥65 years) patients are often considered unfit for transplantation; however, more recent data suggest that older patients, when selected appropriately, tolerate transplantation well. We report our institutional experience with HSCT in patients aged ≥70 years. A cohort of 22 patients underwent HSCT. Median overall survival was 5.16 years [95% confidence interval (CI): 1.5–8.7 years], and median post-transplant survival was 2.2 years (myelodysplastic syndrome: median 1.3 years, 95% CI: 4.7 months–2.2 years; acute myeloid leukemia: median not reached). Thirty-day mortality following HSCT was 9.5% (n = 2). These data provide further support for the use of HSCT in selected older patients, and highlight the impact of HSCT on overall survival among a patient cohort primarily of acute myeloid leukemia and myelodysplasia.
AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade, as understanding of the treatment and its related toxicities has led to changes in patient selection, conditioning regimens, and post-transplant care. Older (age ≥65 years) patients are often considered unfit for transplantation; however, more recent data suggest that older patients, when selected appropriately, tolerate transplantation well. We report our institutional experience with HSCT in patients aged ≥70 years. A cohort of 22 patients underwent HSCT. Median overall survival was 5.16 years [95% confidence interval (CI): 1.5–8.7 years], and median post-transplant survival was 2.2 years (myelodysplastic syndrome: median 1.3 years, 95% CI: 4.7 months–2.2 years; acute myeloid leukemia: median not reached). Thirty-day mortality following HSCT was 9.5% (n = 2). These data provide further support for the use of HSCT in selected older patients, and highlight the impact of HSCT on overall survival among a patient cohort primarily of acute myeloid leukemia and myelodysplasia.
KW - Acute Myeloid Leukemia
KW - Allogeneic Stem Cell Transplant
KW - Bone Marrow Transplant
KW - FLT-3
KW - Hypomethylating agent
KW - Induction Chemotherapy
KW - Leukemia
KW - Myelodysplastic syndrome
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85062405205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062405205&partnerID=8YFLogxK
U2 - 10.1016/j.hemonc.2019.01.002
DO - 10.1016/j.hemonc.2019.01.002
M3 - Article
C2 - 30836091
AN - SCOPUS:85062405205
SN - 1658-3876
VL - 12
SP - 105
EP - 109
JO - Hematology/ Oncology and Stem Cell Therapy
JF - Hematology/ Oncology and Stem Cell Therapy
IS - 2
ER -